INFORMAZIONI SU QUESTO ARTICOLO
Article Category: In My View
Pubblicato online: 21 apr 2018
Pagine: 35 - 37
DOI: https://doi.org/10.17225/jhp.00023
© 2018
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair